

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



ImmuneOnco Biopharmaceuticals (Shanghai) Inc.

宜明昂科生物醫藥技術（上海）股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 1541)

INSIDE INFORMATION ISSUANCE OF FILING NOTICE BY THE CSRC FOR THE H SHARE FULL CIRCULATION OF CERTAIN UNLISTED SHARES OF THE COMPANY

This announcement is made by ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09(2)(a) of the Rules Governing the Listing of Securities (the “**Listing Rules**”) on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) and the Inside Information Provisions under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

Reference is made to the “Guidelines on Application for ‘Full Circulation’ of Domestic Unlisted Shares of H-share Companies” (CSRC Announcement [2023] No. 50) (《H股公司境內未上市股份申請「全流通」業務指引》(中國證監會公告[2023]50號)) (the “**Guidelines**”) issued by the China Securities Regulatory Commission (the “**CSRC**”) on August 10, 2023 regarding the procedures of application by companies whose H shares are listed on the Stock Exchange for circulation of domestic unlisted shares (as defined under the Guidelines) on the Stock Exchange.

The board (the “**Board**”) of directors (“**Directors**”, and each a “**Director**”) of the Company is pleased to announce that the Company has recently received a filing notice issued by the CSRC (the “**Filing Notice**”) regarding the implementation of the H share full circulation of the Company. According to the Filing Notice, the Company has completed the filing with the CSRC in respect of the implementation of conversion up to an aggregate of 120,463,260 unlisted shares of the Company (the “**Unlisted Shares**”) into H shares of the Company (“**H Shares**”). The Filing Notice shall be valid for 12 months from May 14, 2024.

The information of the implementation of the H share full circulation of the Company is set forth in the table below.

No.	Name of Shareholders	Maximum number of Unlisted Shares to be converted
1.	Dr. Tian Wenzhi (田文志)	35,091,495
2.	Shanghai Zhangjiang Leading Initiating Venture Capital (Limited Partnership) (上海張科領弋升帆創業投資中心(有限合夥))	25,750,000
3.	Beijing Lapam Healthcare Investment Centre (Limited Partnership) (北京龍磐健康醫療投資中心(有限合夥))	19,263,240
4.	Jiaxing Changxian Enterprise Management L.P. (Limited Partnership) (嘉興昶咸企業管理合夥企業(有限合夥))	7,758,630
5.	Jiaxing Changyu Enterprise Management L.P. (Limited Partnership) (嘉興昶宇企業管理合夥企業(有限合夥))	7,419,847
6.	Suzhou Likang Equity Investment Centre (Limited Partnership) (蘇州禮康股權投資中心(有限合夥))	7,214,085
7.	Shanghai Zhangjiang Science & Technology Venture Capital Co., Ltd. (上海張江科技創業投資有限公司)	10,862,055
8.	Granite Peak Limited	2,271,082
9.	Ningbo Yaluo Venture Capital Partnership (Limited Partnership) (寧波雅羅創業投資合夥企業(有限合夥)) (formerly known as Shihezi Yaluo Equity Investment Partnership (Limited Partnership) (石河子市雅羅股權投資有限合夥企業))	2,347,150
10.	Borah Peak Limited	1,731,836
11.	Suzhou Lirun Equity Investment Centre (Limited Partnership) (蘇州禮潤股權投資中心(有限合夥))	753,840
Total		120,463,260

The Company will apply to the Stock Exchange for the listing of, and permission to deal in, such H Shares on the Main Board of the Stock Exchange (the “**Conversion and Listing**”).

As at the date of this announcement, the details of implementation plan of the Conversion and Listing have not been finalized. The Company will make further announcements on the progress of the Conversion and Listing in compliance with the requirements under Listing Rules and the applicable laws, as and when appropriate.

The Conversion and Listing are subject to other relevant procedures as required by the Stock Exchange and other domestic and overseas regulatory authorities. Shareholders of the Company and potential investors are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
Tian Wenzhi
Chairman and Executive Director

Hong Kong, May 29, 2024

As at the date of this announcement, the Board of Directors comprises (i) Dr. Tian Wenzhi, Mr. Li Song and Ms. Guan Mei as executive Directors; (ii) Dr. Xu Cong, Mr. Yu Zhihua and Mr. Yu Xiaoyong as non-executive Directors; and (iii) Dr. Zhenping Zhu, Dr. Kendall Arthur Smith and Mr. Yeung Chi Tat as independent non-executive Directors.